As the frenzy around Generative AI continues to heighten, each stakeholder in the system (ML engineers, scientists, and end users) continue to calibrate their viewpoints on the promise of the technology. Some are convinced that this is a fad that will pass. To be fair, it has happened before. Remember, Segway was supposed to change urban transportation but ended as a punchline.
Some others continue to believe in the promise but at the same time refine and recalibrate their viewpoints with new developments. We fall into this category. As conjectures follow, I think Generative AI is a big-tent technology and multiple viewpoints can and will co-exist. We should of course feel free to change our views one way or another as we learn more.
Before we dig deeper, I will narrow down the scope of this conversation. First- since my experiences and awareness are largely limited to the life sciences industry, I will stay in that lane. Second, I feel there are 4 different categories of expertise emerging around LLMs based on the scale of $$, Compute power, and, Skills required:
Just to set the context we are somewhere at the interface of group 2 and group 3.
Now, let us dig deeper!
The pharma and biotech industries have already started using artificial intelligence to improve efficiency, generate reports, and develop drugs. But like I already said, this is an uncharted territory, we are early adopters, and only time can validate the potential of the technology. Meanwhile, here are 3 ways
We will be discussing more about Generative AI in our annual event DataFAIR 2023 which will be held virtually on the 26th of October between 1PM and 4PM EST. Join us to hear from the best minds in the Biopharma/ Biotech space to explore the revolutionary potential of Generative AI in drug discovery. Click here!
Get the latest insights on Biomolecular data and ML